6 hours Regeneron Gains 13.5% Year to date: How to Play the Stock? Zacks
REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.
Pharmaceuticals · Regeneron Pharma (REGN)
REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.
Pharmaceuticals · Regeneron Pharma (REGN)